Effectiveness and safety of treatment for heterozygous familial hypercholesterolaemia and multifactorial dyslipidaemia in children: an overview of systematic reviews
Open Access
- 30 March 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (9) , 1532-1547
Abstract
Aims: This overview of systematic reviews (SRs) summarizes evidence on effectiveness and safety of treatment for paediatric heterozygous familial hypercholesterolaemia (heFH) and multifactorial dyslipidaemia (MFD). Methods and results: MEDLINE, EMBASE, Cochrane, and Epistemonikos were systematically searched for relevant SRs of randomized controlled trials (RCTs) published 01.01.2015-16.05.2024, with updated search until 31.01.2025. Systematic reviews on different therapeutic interventions assessing surrogate and long-term health outcomes were eligible. AMSTAR-2 was used to appraise SRs and GRADE to evaluate certainty of evidence (CoE). Eight SRs were included and high-quality ones prioritized for further analysis. Among children with heFH, in a meta-analysis of six RCTs (n = 669), statins significantly reduced cholesterol levels compared with placebo over a 2-year follow-up (mean difference, MD: −32.15%; 95% confidence interval, CI: −34.9; −29.4 for LDL-cholesterol; moderate CoE). Significant reductions in LDL-cholesterol levels were also observed for ezetimibe (1 RCT, n = 127; MD: −63 mg/dL; 95% CI: −79.5; −46.5) and PCSK9 inhibitors, with MD in change of −43.3% to −33.8% for evolocumab (1 RCT, n = 157) and alirocumab (1 RCT, n = 153), respectively (moderate CoE). Bile acid sequestrants and fibrates showed significant lipid-lowering effects; however, CoE was low/very low. No significant differences in adverse events during short-term follow-up were observed between study groups for all drugs. Non-pharmacological interventions mainly did not improve lipid profile in paediatric FH (CoE very low). Among children with MFD, behavioural counselling demonstrated modest lipid-lowering effects that attenuated overtime (2 RCTs; low CoE). Conclusions: In summary, statins are effective lipid-lowering therapy in paediatric FH, with long-term safety requiring further investigation. Evidence evaluating non-pharmacological interventions for childhood dyslipidaemia is sparse.Keywords
Funding Information
- Innovation Committee of the German Joint Federal Committee of Physicians and Public Health Insurances (01VSF23011)
- German Ministry of Education and Research
- German Center for Child and Adolescent Health (01GL2406A)
- Else Kröner-Fresenius-Stiftung
- LMU University Hospitals
This publication has 67 references indexed in Scilit:
- Alirocumab in Pediatric Patients With Heterozygous Familial HypercholesterolemiaJAMA Pediatrics, 2024
- Screening for Lipid Disorders in Children and AdolescentsJAMA, 2023
- Still “on the Fence” About Universal Childhood Lipid ScreeningJAMA, 2023
- Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trialsEndocrine, 2020
- Reducing the Clinical and Public Health Burden of Familial HypercholesterolemiaJAMA Cardiology, 2020
- Lipid Screening in Childhood and Adolescence for Detection of Multifactorial DyslipidemiaJAMA, 2016
- Flaxseed in Pediatric HyperlipidemiaJAMA Pediatrics, 2013
- Efficacy and Safety of Statin Therapy in Children With Familial HypercholesterolemiaJAMA, 2004
- Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial HypercholesterolemiaJAMA, 1999
- Efficacy and Safety of Lowering Dietary Intake of Fat and Cholesterol in Children With Elevated Low-Density Lipoprotein CholesterolJAMA, 1995